NCT00415051View on ClinicalTrials.gov

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2009

Conditions
Rift Valley Fever
Interventions
BIOLOGICAL

RVF MP-12

Administer 1 ml SQ

Trial Locations (1)

21702

US Army Medical Research Institute of Infectious Diseases, Fort Deterick

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT00415051 - Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine | Biotech Hunter | Biotech Hunter